Get the Stockscreener App
184.60
0.53%
-0.98
After Hours:
184.74
0.14
+0.08%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $184.60, with a volume of 7.80M.
It is down -0.53% in the last 24 hours and up +2.65% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$185.58
Open:
$185.75
24h Volume:
7.80M
Relative Volume:
1.09
Market Cap:
$351.09B
Revenue:
$57.37B
Net Income/Loss:
$4.20B
P/E Ratio:
78.55
EPS:
2.35
Net Cash Flow:
$17.83B
1W Performance:
-6.99%
1M Performance:
+2.65%
6M Performance:
-7.47%
1Y Performance:
+15.09%
1-Day Range:
$184.23
$189.77
1-Week Range:
$181.64
$198.50
52-Week Range:
$153.58
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
184.60 | 351.09B | 57.37B | 4.20B | 17.83B | 2.35 |
|
LLY
Lilly Eli Co
|
734.57 | 739.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.22 | 375.64B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
65.77 | 307.32B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
108.70 | 225.73B | 53.22B | 12.86B | 14.85B | 6.39 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025CERE | FinancialContent - FinancialContent
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inc. (ABBV): Among the Best Income Stocks to Invest in Now - Insider Monkey
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight - GuruFocus
Contract Research and Manufacturing Services (CRAMS) Business Report 2025: Market to Reach $211.4 Billion by 2030, Fueled by Growing Demand for Biologics and Biosimilars - GlobeNewswire Inc.
June 27th Options Now Available For AbbVie - Nasdaq
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to JoinContact The Gross Law Firm - Morningstar
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks - Yahoo Finance
Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink? - Nasdaq
AbbVie’s Skyrizi leads pharma TV ad rankings for April - Medical Marketing and Media
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV - TradingView
AbbVie Files Suit Challenging Tennessee’s Contract Pharmacy Law - Bloomberg Law News
Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera - The Globe and Mail
Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com
The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie - TradingView
Are Wall Street Analysts Predicting AbbVie Stock Will Climb Or Sink? - Barchart.com
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
AbbVie to Present at the Bank of America Securities Healthcare C - GuruFocus
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects? - TradingView
AbbVie to Present at the Bank of America Securities Healthcare Conference - Yahoo Finance
AbbVie (ABBV) Set for Gains with Medicare Policy Shift | ABBV St - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com
AbbVie (ABBV) Set for Gains with Medicare Policy Shift | ABBV Stock News - GuruFocus
ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations - Yahoo Finance
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security ConcernsiShares Biotechnology ETF (NASDAQ:IBB), AbbVie (NYSE:ABBV) - Benzinga
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com
AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth with a 6.15% Upside Potential - DirectorsTalk Interviews
Viral Conjunctivitis Drugs Market Overall Study Report - openPR.com
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance
Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV) - GuruFocus
Fund Update: SATURNA CAPITAL CORP added 40,521 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Conta - GuruFocus
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - AbbVie News Center
AbbVie shares snap seven-session gaining streak - MSN
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV - marketscreener.com
Class Action Filed Against Cerevel Therapeutics Holdings, - GlobeNewswire
PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid - Law360
Androgen Drugs Market Detailed in New Research Report By 2032 | AbbVie Inc.,Endo International plc - openPR.com
FDA approves AbbVie’s upadacitinib for giant cell arteritis - Yahoo Finance
AbbVie secures FDA approval for Rinvoq to treat giant cell arteritis - World Pharmaceutical Frontiers
In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis - insights.citeline.com
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis - Benzinga
Why AbbVie Stock Topped the Market Today - MSN
AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis - Yahoo Finance
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
AbbVie Says Rinvoq Medication Gets FDA Approval to Treat Giant Cell Arteritis - marketscreener.com
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):